Thursday 7 May, 2026
Introduction: Achondroplasia (ACH) is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant leading…
Read morePoster: Drug/Disease Modelling - Endocrine
Vicadrostat Pharmacodynamics and steroidogenesis validated and explained: A mechanistic QSP model
Thursday 7 May, 2026
Background & Objectives: Selective aldosterone synthase inhibitors (ASi), such as vicadrostat, are being developed to prevent or slow the progression…
Read moreBiomarker-Guided Dose Selection Facilitated by a C-Peptide Model in Type 1 Diabetes Patients
Thursday 7 May, 2026
Introduction There is no approved disease-modifying therapy for new-onset Type 1 Diabetes (NOT1D). Although rabbit anti-thymocyte globulin (rATG) is effective…
Read morePopulation Pharmacokinetics of Olokizumab in Healthy Volunteers and Rheumatoid Arthritis Subjects
Thursday 7 May, 2026
Objectives: Olokizumab (OKZ) is a humanized monoclonal antibody developed as an antagonist of interleukin-6 and used for the treatment of…
Read moreINTEGRATED POPULATION PHARMACOKINETIC-PHARMACODYNAMIC-EFFICACY ANALYSIS OF ENAVOGLIFLOZIN: LINKING EXPOSURE, GLUCOSURIA, AND HBA1C REDUCTION IN TYPE 2 DIABETES
Thursday 7 May, 2026
Objectives (167 words): Sodium-glucose cotransporter 2 (SGLT2) inhibitors are oral antihyperglycemic agents for the treatment of type 2 diabetes (T2D)…
Read moreLONGITUDINAL MODELLING OF CARDIOMETABOLIC DYSFUNCTION IN PATIENTS WITH TYPE 2 DIABETES USING ITEM RESPONSE THEORY
Thursday 7 May, 2026
Introduction/Objectives: Metabolic syndrome (MetS) is a cluster of metabolic disorders including obesity, dyslipidemia, hypertension, and insulin resistance [1]. Type 2…
Read moreMODELLING DOSE-RESPONSE AND PATIENT ENROLMENT ACROSS MULTIPLE IVF TREATMENT CYCLES OF FOLLITROPIN DELTA
Thursday 7 May, 2026
Introduction: In vitro fertilisation (IVF) involves stimulating the development of multiple ovarian follicles using follicle-stimulating hormone (FSH) to achieve pregnancy….
Read moreTOWARDS AN INTEGRATED METABOLISM QUANTITATIVE SYSTEMS PHARMACOLOGY (QSP) MODEL FOR SUPPORTING A PIPELINE OF OBESITY THERAPEUTICS
Thursday 7 May, 2026
Introduction: Incretin-mimetic drugs (IMDs) such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP) receptor agonists have revolutionized obesity treatment,…
Read moreA Physiologically-Based Quantitative Systems Pharmacology (PB-QSP) Model for Individualized Prediction of Treatment Outcomes with Alogliptin in the Renal Impairment Population
Thursday 16 October, 2025
Introduction: Type 2 diabetes is considered to be one of the most significant health problems affecting the world, and prolonged…
Read moreAssessing Glucagon Kinetics through Nonlinear Mixed Effects Modeling
Thursday 16 October, 2025
Objectives:A concomitance of both defective insulin secretion and impaired glucagon suppression leads to the development of impaired glucose tolerance in…
Read more